|
|
|
| |
|
|
|
|
|
CUSIP No.
759408107
|
|
13D
|
|
Page 3 of 4 Pages
|
|
|
|
|
|
Item 1. Security and Issuer.
This statement relates to the $0.001 par value common stock of Rejuvel Bio-Sciences, Inc. (the Issuer). The issuers principal executive offices are located at 15800 Pines Blvd., Suite 3116 Pembroke Pines, Florida, 33027.
Item 2. Identity and Background.
This statement is being filed by Charles J Scimeca (the Reporting Person).
The business address of the Reporting Person is 15800 Pines Blvd., Suite 3116 Pembroke Pines, Florida, 33027.
The
principal business of the Reporting Person is as the President , Secretary, Treasurer, and a Director of Issuer.
The Reporting Person has not, during the last five years, been convicted in a criminal proceeding (excluding traffic violations or similar misdemeanors).
The Reporting Person has not, during the last five years, been a party to a civil proceeding of a judicial or administrative body of competent jurisdiction and as a result of such proceeding was or is subject to a judgment, decree or final order enjoining future violations of, or prohibiting or mandating activities subject to, federal or state securities laws or finding any violation with respect to such laws.
The Reporting Person is a citizen of the United States (Florida).
Item 3. Source or Amount of Funds or Other Consideration.
On January 19, 2017, the Board of Directors issued 1,250,000 shares of Series A Preferred Stock to Mr. Scimeca, for entering that certain Employment Agreement with the Company and retirement debt and deferred compensation. On April 30, 2017 , the Board of Directors issued 59,000 shares of Series A Preferred Stock to Mr. Scimeca for the company being in default of money relating to the Employment Agreement.
Item 4. Purpose of Transaction.
The purpose of the transaction was to Compensate the Reporting Person for forgives of debt and a default by company.
Item 5. Interest in Securities of the Issuer.
As of the date hereof, the Reporting Person currently beneficially owns 355,190,881 shares of the Issuers common stock, which represent 30.161% of the Issuers issued and outstanding common stock (based on 1,177,647,077 shares of the Issuers common stock outstanding as of May 24, 2017) and 33. 417% ( based on 3,938,919 shares of the issuers Preferred Series A outstanding as of May 24, 2017 and 50.029% based on 14,008,159 shares of the issuers Preferred Series C outstanding as of May 24, 201
The Reporting Person exerts sole voting and dispositive control over the securities held by him and Coast To Coast Equity Group, Inc. an affiliate.
The Reporting Person has gifted 0 shares in the common stock, during the past sixty days.
To the best of the knowledge of the Reporting Person, no person other than the Reporting Person has the right to receive, or the power to direct the receipt of, dividends from, or the proceeds from the sale of any class of shares of the Issuer reported in Item 5(a).
Not Applicable.
Item 6. Contracts, Arrangements, Understandings or Relationships with Respect to Securities of the Issuer.
Except as described above, there are no contracts, agreements, understandings or relationships (legal or otherwise) between the Reporting Person and any other person with respect to any securities of the Issuer.
Item 7. Material to Be Filed as Exhibits.
Not Applicable.
|
|
|
| |
|
|
|
|
|
CUSIP No.
759408107
|
|
13D
|
|
Page 4 of 4 Pages
|
|
|
|
|
|
SIGNATURE
After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
|
|
Rejuvel Bio-Sciences, Inc.
|
|
/s/
Charles J. Scimeca
Charles J. Scimeca
|
|
President,
Secretary, Treasurer and Director
|
|
June 8, 2017
|